New IHE report examines capacity use in subcutaneous and intravenous immunotherapy for lung cancer

Based on data from three Swedish lung clinics, the study shows that subcutaneous administration can reduce staff time, chair occupancy, and overall capacity strain — while maintaining comparable clinical efficacy. The findings highlight the potential for more efficient care delivery as demand for immunotherapy continues to grow.